Sartorius Stedim stock gets higher analyst targets amid recovery hopes
Published on 10/05/2026 at 13:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius Stedim Biotech (ISIN FR0013154002) was trading at EUR 207.40 on Euronext Paris on October 5, 2026 at 12:51 p.m. CEST, down 0.38 percent from the previous close. The latest analyst revisions remain the central market story: Oddo BHF raised its price target from EUR 239 to EUR 281 on October 2, 2026, while maintaining an Outperform rating, according to Ideal Investisseur.
Higher targets meet fresh results
The Oddo BHF revision followed Goldman Sachs raising its target from EUR 208 to EUR 223 on October 1, 2026, while retaining a Buy rating, the same report said. The two changes point to a broader reassessment of Sartorius Stedim's earnings recovery rather than a single isolated recommendation.
That reassessment has a fresh operating basis. Sartorius Stedim reported first-half 2026 revenue of EUR 1,527.0 million, EBITDA of EUR 463.7 million and an EBITDA margin of 31.4 percent, according to Ideal Investisseur. Management guidance cited in the report calls for 2026 revenue of EUR 3,154.0 million and EBITDA of EUR 989.2 million.
Consensus leaves a 20.54 percent gap
A separate analyst overview published on September 30, 2026, listed three analysts with a Buy recommendation and an average price target of EUR 250.00, according to Finanzen. That average target lies 20.54 percent above the EUR 207.40 price on October 5, 2026, using the Euronext Paris quotation as the reference.
The valuation already reflects demanding expectations. The same October 5 market coverage put the estimated 2026 price-to-earnings ratio at 41.40, while the 52-week range stood at EUR 150 to EUR 224. The current price was 7.41 percent below the 52-week high, leaving the recovery thesis dependent on the company converting its guidance into reported growth.
Stock remains below its yearly high
Sartorius Stedim was last at EUR 207.40 on Euronext Paris on October 5, 2026 at 12:51 p.m. CEST. Its market capitalization was EUR 20.2 billion and session volume was 9,915 shares.
Sartorius Stedim stock facts
- Company: Sartorius Stedim Biotech S.A.
- ISIN: FR0013154002
- Ticker: DIM
- Trading venue: Euronext Paris
- Price (as of October 5, 2026, 12:51 p.m. CEST): EUR 207.40
- Market capitalization: EUR 20.2 billion (as of October 5, 2026)
- 52-week range: EUR 150-224 (as of October 5, 2026)
- Sector / Industry: Medical supplies and bioprocessing equipment
- Index membership: SBF 120
